Stevanato Group SpA Q3 FY2026 earnings call

• GLP-1 Market Dynamics: GLP-1 related revenue is approximately 17-18% of total company revenue. While non-GLP biologics grew over 30% in Q3, management expects lower GLP volumes for 2027 due to a temporary headwind from one major customer.
• Backfilling Strategy: Management has backfilled the majority of the anticipated GLP-1 volume shortfall through strong demand in non-GLP biologics, specifically Alba syringes, EasyFill cartridges, and drug delivery systems. This allows them to maintain low single-digit growth expectations for 2027.
• Operational Improvements: The Fishters facility achieved gross profit breakeven in Q3. Production lines for EasyFill cartridges and vials are ramping up in Latina and Piombino d'Ese. The ALINA pen injector program is gaining traction with multiple customers.
• Engineering Segment Challenges: Operations have stabilized, but new order intake was below targets due to delays from a large customer. Management is reassessing the strategic fit of the engineering division's visual inspection business relative to its high-value core.
• Long-Term Outlook: Despite the 2027 moderation, management remains confident in long-term growth driven by biosimilar pipelines, aging populations, and the shift to self-administration. They expect to return to high-single-digit/low-double-digit growth rates post-2027.

• BDS (Biopharmaceutical and Diagnostic Solutions): Revenue of $294 million, up 10% reported and 11% organic. High-value solutions contributed $149.4 million (approx. 51% of segment revenue), while other containment/delivery solutions grew 23% to $144.6 million.
• Engineering: Revenue declined 12% to $32 million due to lower sales in pharma visual inspection and assembly/packaging. Gross margin fell 20 bps to 10.2%, though operating margin improved 220 bps to 1.1% due to cost optimization.

• Full Year 2026 Revenue: Reiterated at $1.26 billion to $1.28 billion.
• Full Year 2026 Adjusted EBITDA: Reiterated at $335 million to $345.2 million.
• Full Year 2026 Adjusted Diluted EPS: Reiterated at $0.60 to $0.62.
• Engineering Segment Revenue Update: Revised downward to $124 million–$134 million, offset by stronger BDS growth.
• CAPEX Update: Revised upward to $230 million–$240 million (net of customer contributions: $215 million–$225 million).
• 2027 Outlook: Expectation of low single-digit revenue growth, down from long-range plans of high-single-digit to low-double-digit growth, due to the temporary GLP-1 volume headwind.

• GLP-1 Volume Volatility: Temporary reduction in volumes from a key GLP-1 customer may moderate 2027 growth.
• Engineering Order Delays: Significant delays in converting pipeline orders into signed contracts for a large customer have impacted 2026 results.
• Utility Costs: Increased energy and gas prices in Europe negatively impacted gross margins in Q3; ongoing price adjustment negotiations with customers are required.
• Strategic Execution Risk: Continued assessment of the engineering division's future role creates uncertainty regarding resource allocation and focus.

Q: Is the variable compensation received from the GLP-1 customer a 'take-or-pay' clause, and can it be quantified? / A: CFO Marco Dal Lago confirmed that contractual protections vary by customer, including take-or-pay, minimum quantities, and capacity reservations. He stated that while specific contract details cannot be disclosed, the compensation recognized in Q3/Q4 is not material to the quarter or year, reflecting that the volume shortfall was partially mitigated by these clauses.

Q: Is the GLP-1 headwind concentrated in a single customer or widespread across the market? / A: CEO Franco Stevanato confirmed the temporary headwind is tied to one specific customer. He noted that this customer is a market leader and the issue is likely due to early-stage launch fluctuations or inventory adjustments rather than a loss of share. Management remains confident in the long-term relationship and the broader GLP-1 opportunity.

Q: What drives the strong growth in non-GLP biologics, and how does this support 2027 guidance? / A: Management highlighted robust demand across multiple therapeutic areas (immunology, oncology, etc.) driving growth in Alba syringes, EasyFill cartridges, and drug delivery systems. This diversified demand has allowed the company to backfill most of the GLP-1 shortfall, enabling them to maintain low single-digit growth for 2027 despite the temporary headwind.

Q: Are the delays in the Engineering segment related to the same GLP-1 customer? / A: Yes, the delays in converting the engineering pipeline to orders are linked to the same key customer experiencing GLP-1 volume issues. However, management emphasized that operational improvements continue, and the delay is primarily in the commercial negotiation phase rather than technical capability.

Q: How do utility cost increases impact margins, and what is the outlook for Q4? / A: CFO Dal Lago explained that higher European gas prices unfavorably impacted Q3 gross margins. While long-term agreements allow for price adjustments, these take time. Management assumes Q4 utilities will remain slightly above Q3 levels, embedded in their current guidance, but is confident in managing the situation through customer negotiations.